Diagnosis and treatment of the hepatic porphyrias.
Porphyrias are a peculiar group of diseases resulting from hereditary or acquired partial deficiencies in seven of the eight enzymes in the biosynthetic pathway of heme. Biosynthesis of heme takes place in the erythropoietic system or in the hepatic tissue. Depending on the main location of the enzyme defect, porphyrias can be classified as erythropoietic or hepatic. There are seven basic clinical forms of porphyria related to a deficiency of each of the involved enzymes. Clinical manifestations in porphyria may be neurovisceral or cutaneous. Patients may present with acute attacks (acute porphyrias), cutaneous lesions (cutaneous porphyrias), or both (mixed porphyrias). Study of patients supected of having porphyria should include several steps: 1) clinical evaluation, 2) biochemical study, which enables us to classify the patient to a specific form of porphyria, followed if possible by 3) enzymatic assay(s), and 4) genetic studies to confirm an enzyme deficiency and its level and the causal genetic mutation. Unfortunately no curative treatment is available for any of the porphyrias. However, symptomatic treatments are available and are discussed in this article.
Lecha
M
M
Department of Dermatology, Hospital Clinic, University of Barcelona, Barcelona, Spain. 4908mlc@comb.es
Herrero
C
C
Ozalla
D
D
D000208:Acute Disease; D000962:Antimalarials / Q000627:therapeutic use; D002738:Chloroquine / Q000627:therapeutic use; D006418:Heme / Q000096:biosynthesis; D006801:Humans; D010787:Photosensitivity Disorders / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy*; D017094:Porphyrias, Hepatic / Q000175:diagnosis* / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy*; D011166:Porphyrins / Q000097:blood
D000962:Antimalarials; D011166:Porphyrins; D006418:Heme; D002738:Chloroquine